Compare AbbVie Inc (ABBV) vs Conagra Brands Inc (CAG) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Conagra Brands (CAG) trades at $15.11, up 1.75% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $11.6B revenue and $1.15B net income, but faces challenges with negative margins projected for 2026. Recent developments include a 50% dividend cut to $0.18 and new leadership appointments under CEO John Brase, who recently purchased 35,000 shares.

The outlook remains cautious despite attractive valuation metrics (P/E 10.06, P/S 0.64). While analyst consensus leans Hold (62.5%), the stock trades above the $13.67 target. Key risks include persistent inflation pressure, declining sales, and margin compression. The dividend reduction provides financial flexibility but signals ongoing turnaround challenges.